Mazvita Muchengeti1,2, Julia Bohlius3,4, Tafadzwa G Dhokotera1,3,4,5. 1. National Cancer Registry, National Health Laboratory Service. 2. Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. 3. Institute of Social and Preventive Medicine, University of Bern, Bern. 4. Swiss Tropical and Public Health Institute, University of Basel, Basel. 5. Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Abstract
PURPOSE OF REVIEW: Historically, conjunctival cancer has been associated with HIV particularly in sub-Saharan Africa. The human papilloma virus (HPV) has been implicated as a potential causative agent without conclusive evidence. This review covers recent evidence of the epidemiology, diagnosis and treatment of conjunctival cancer in people living with HIV (PLWH). RECENT FINDINGS: HIV infection has been attributed to 33% of squamous cell carcinoma of the conjunctiva in sub-Saharan Africa. Although clear evidence of the effect of immunodeficiency on conjunctival cancer risk has been demonstrated, the role of HPV on conjunctival cancer development is still unclear. Biomarkers such as the p16 protein are not always indicative of HPV infection. The Epstein-Barr virus (EBV) might potentially be another infectious agent of interest in the development of conjunctival cancer. There is some evidence of increased conjunctival cancer recurrence post treatment as well as increased probability of metastasis in PLWH. SUMMARY: Immunodeficiency increases the risk of conjunctival cancer in PLWH. Symptomatic screening of conjunctival cancer in PLWH should be encouraged. Research on HPV involvement should remain a priority and EBV considered as another etiologic agent of interest. More studies on treatment modalities in PLWH should be considered.
PURPOSE OF REVIEW: Historically, conjunctival cancer has been associated with HIV particularly in sub-Saharan Africa. The human papilloma virus (HPV) has been implicated as a potential causative agent without conclusive evidence. This review covers recent evidence of the epidemiology, diagnosis and treatment of conjunctival cancer in people living with HIV (PLWH). RECENT FINDINGS: HIV infection has been attributed to 33% of squamous cell carcinoma of the conjunctiva in sub-Saharan Africa. Although clear evidence of the effect of immunodeficiency on conjunctival cancer risk has been demonstrated, the role of HPV on conjunctival cancer development is still unclear. Biomarkers such as the p16 protein are not always indicative of HPV infection. The Epstein-Barr virus (EBV) might potentially be another infectious agent of interest in the development of conjunctival cancer. There is some evidence of increased conjunctival cancer recurrence post treatment as well as increased probability of metastasis in PLWH. SUMMARY: Immunodeficiency increases the risk of conjunctival cancer in PLWH. Symptomatic screening of conjunctival cancer in PLWH should be encouraged. Research on HPV involvement should remain a priority and EBV considered as another etiologic agent of interest. More studies on treatment modalities in PLWH should be considered.
Authors: Lucia Hämmerl; Jacques Ferlay; Margaret Borok; Carla Carrilho; Donald Maxwell Parkin Journal: Cancer Epidemiol Date: 2019-06-27 Impact factor: 2.984
Authors: Cesaltina F Lorenzoni; Josefo Ferro; Carla Carrilho; Murielle Colombet; Donald M Parkin Journal: Int J Cancer Date: 2020-03-18 Impact factor: 7.396
Authors: Carla Carrilho; Chau Miu; Yeji Kim; Susan Karki; Alexandra Balmaceda; Bindu Challa; Scott Diamond; Eliane Monteiro; Evelia Marole; Cesaltina Lorenzoni; Yolanda Zambujo; Yu-Tsueng Liu; Robert T Schooley; Jonathan H Lin Journal: Ocul Oncol Pathol Date: 2019-09-05
Authors: Lauren E Merz; Osei Afriyie; Evelyn Jiagge; Ernest Adjei; Susan K Foltin; Megan L Ludwig; Jonathan B McHugh; J Chad Brenner; Sofia D Merajver Journal: Health Sci Rep Date: 2019-01-10